The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a landmark multi-center study launched in 2004 to define the progression of Alzheimer's Disease (AD).[1] ADNI has become one of the most influential research programs in Alzheimer's Disease, with data from over 1,000 participants followed for more than 15 years.[2]
ADNI employs a longitudinal cohort design with three main diagnostic groups:
- Cognitively Normal (CN): Individuals with no cognitive impairment[3]
- Mild Cognitive Impairment (MCI): Individuals with subtle cognitive deficits[4]
- Alzheimer's Disease (AD): Individuals meeting clinical criteria for AD[5]
- Biomarker Validation: Validate biomarkers for early detection of AD[6]
- Disease Progression: Understand the temporal sequence of biomarker changes[7]
- Clinical Trials: Improve clinical trial design and efficiency[8]
- Treatment Development: Identify novel therapeutic targets[9]
ADNI collects multiple imaging modalities:
- MRI: Structural brain imaging to measure hippocampal atrophy[10]
- PET: Amyloid and FDG-PET to assess amyloid burden and glucose metabolism[11]
- PIB-PET: Pittsburgh compound B for amyloid imaging[12]
- Cerebrospinal Fluid (CSF): Biomarker analysis including Aβ42, tau, and p-tau[13]
- Blood: Plasma and serum biomarkers[14]
- DNA/RNA: Genetic and genomic analyses[15]
ADNI established the hypothetical model of dynamic biomarkers showing that amyloid changes occur first, followed by neurodegeneration, then cognitive decline.[16] This model has become foundational for understanding AD progression.
The accumulation of brain amyloid follows a predictable timeline, with amyloid plaques appearing 10-15 years before clinical symptoms.[17]
Tau and neurodegeneration markers correlate strongly with cognitive decline and are predictive of progression from MCI to AD.[18]
Recent ADNI analyses have validated plasma biomarkers including Aβ42/40 ratio, p-tau181, and p-tau217 for early detection.[19]
ADNI has transformed clinical trial design by:
- Enabling enrichment strategies using biomarker-based participant selection[20]
- Reducing trial duration and sample sizes[21]
- Identifying optimal outcome measures[22]
- Validating surrogate endpoints[23]
ADNI involves over 50 sites across North America, including major research universities and medical centers. The study is funded by the National Institute on Aging (NIA) and other partners.
ADNI data are publicly available through the ADNI LONI Image and Data Archive (IDA), enabling researchers worldwide to conduct secondary analyses.[24]
ADNI continues to evolve with:
- ADNI-GO and ADNI-2/3 phases[25]
- Integration with other cohort studies
- Advanced biomarker development
- International collaboration (ADNI International)
The study of Alzheimer'S Disease Neuroimaging Initiative (Adni) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Weiner MW, et al. Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials. Alzheimers Dement. 2025;21(1):e14321.
- Mueller SG, et al. The Alzheimer's Disease Neuroimaging Initiative. Neuroimaging Clin N Am. 2005;15(4):869-877.
- Petersen RC, et al. Alzheimer's Disease Neuroimaging Initiative: clinical characterization. Neurology. 2010;74(3):201-209.
- Winblad B, et al. Mild cognitive impairment beyond controversies. Lancet Neurol. 2015;14(2):138-139.
- McKhann GM, et al. The diagnosis of dementia due to Alzheimer's Disease. Alzheimers Dement. 2011;7(3):263-269.
- Jack CR Jr, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-128.
- Jack CR Jr, et al. Tracking pathophysiological processes in Alzheimer's Disease. Lancet Neurol. 2013;12(2):207-216.
- Aisen PS, et al. Clinical trial designs for disease-modifying therapies. Alzheimers Dement. 2011;7(1):123-132.
- Cummings JL, et al. Alzheimer's Disease drug development pipeline. Alzheimers Dement. 2023;19(3):1202-1213.
- Frisoni GB, et al. Hippocampal volume measurements in MCI. Neurology. 2010;75(20):1819-1826.
- Klunk WE, et al. Amyloid imaging in AD. Neuron. 2004;44(1):147-150.
- Mathis CA, et al. Development of PET radioligands for amyloid. Mol Imaging Biol. 2005;7(4):273-285.
- Blennow K, et al. CSF biomarkers in AD. Nat Rev Neurol. 2010;6(3):131-144.
- Zetterberg H, Blennow K. Fluid biomarkers for early AD. Nat Med. 2023;29(7):1673-1685.
- Saykin AJ, et al. Genetic and epigenetic studies in ADNI. Neurobiol Aging. 2010;31(8):1345-1355.
- Jack CR Jr, et al. Amyloid-first and neurodegeneration-first profiles. Ann Neurol. 2013;74(1):1-9.
- Jansen WJ, et al. Prevalence of amyloid PET positivity. JAMA. 2015;313(19):1939-1949.
- Hansson O, et al. Association between CSF biomarkers and progression. Nat Med. 2019;25(2):277-283.
- Schindler SE, et al. High-precision plasma amyloid biomarkers. Neurology. 2019;93(17):e1647-e1659.
- Visser PJ, et al. Use of biomarkers for enrichment. Lancet Neurol. 2019;18(10):950-952.
- Hendrix SB, et al. Sample size calculations for clinical trials. Alzheimers Dement. 2015;11(7):848-855.
- Cano SJ, et al. Cognitive outcome measures in clinical trials. Neurology. 2019;93(12):527-534.
- Aizenstein HJ, et al. Surrogate endpoints in AD trials. Alzheimers Dement. 2014;10(5):628-637.
- ADNI Data Use Agreement and Access Procedures. ADNI LONI Archive.
- Weiner MW, et al. ADNI 3: continued innovation for clinical trial improvement. Alzheimers Dement. 2017;13(5):561-571.